Objective registration and interpretation of adverse events: An essential element of vaccination;Objectieve registratie en interpretatie van vaccinbijwerkingen: Een essentieel element van vaccinatie

Nederlands Tijdschrift voor Geneeskunde

Volumn 151, Issue 49, 2007, Pages 2707-2708

  Boot, H J ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; PERTUSSIS VACCINE;

DRUG INFORMATION; DRUG SURVEILLANCE PROGRAM; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HUMAN; MEDICAL INFORMATION; PERTUSSIS; PUBLIC HEALTH SERVICE; REGISTRATION; REVIEW; UNSPECIFIED SIDE EFFECT; VACCINATION; WHOLE CELL;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, FACTUAL; DISCLOSURE; HUMANS; NETHERLANDS; VACCINATION;

EID: 37049021986     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Labadie J, Grootheest AC van. Meldingen van bijwerkingen van vaccins bij het Nederlands Bijwerkingen Centrum Lareb in 2004-2006. Ned Tijdschr Geneeskd. 2007;151:2738-42.
2. Maas NAT van der, David S, Kemmeren JM, Vermeer-de Bondt PE. Veiligheidsbewaking van Rijksvaccinatieprogramma; minder bijwerkingen van DKTP-Hib-combinatievaccin sinds overgang in 2005 naar vaccin met acellulaire kinkhoestcomponent. Ned Tijdschr Geneeskd. 2007;151:2732-7.
3. Liang X, Zhang Y, Xu W, Wen N, Zuo S, Lee LA, et al. An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China. J Infect Dis. 2006;194:545-51.
4. Centers for Disease Control and Prevention (CDC). Intussusception among recipients of rotavirus vaccine - United States, 1998-1999. MMWR Morb Mortal Wkly Rep. 1999;48:577-81.
5. Centers for Disease Control and Prevention (CDC). Suspension of rotavirus vaccine after reports of intussusception - United States, 1999. MMWR Morb Mortal Wkly Rep. 2004;53:786-9.
6. Vesikari T, Matson DO, Dennehy P, van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. Rotavirus Efficacy and Safety Trial (REST) Study Team. N Engl J Med. 2006;354:23-33.
7. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. Human Rotavirus Vaccine Study Group. N Engl J Med. 2006;354:11-22.
8. Centers for Disease Control and Prevention (CDC). Postmarketing monitoring of intussusception after RotaTeq vaccination - United States, 2006-2007. MMWR Morb Mortal Wkly Rep. 2007;56:218-22.
9. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351:637-41.
10. Murch SH, Anthony A, Casson DH, Malik M, Berelowitz M, Dhillon AP, et al. Retraction of an interpretation. Lancet. 2004;363:750.
11. Oosten M van, Boer AS de. BMR-vaccinatie en autisme. Infectieziekten Bulletin. 2005;16:171-4.
12. Jansen VA, Stollenwerk N, Jensen HJ, Ramsay ME, Edmunds WJ, Rhodes CJ. Measles outbreaks in a population with declining vaccine uptake. Science. 2003;301:804.
13. Demicheli V, Rivetti A, di Pietrantonj C, Clements CJ, Jefferson T. Hepatitis B vaccination and multiple sclerosis: evidence from a systematic review. J Viral Hepat. 2003;10:343-4.
14. Hernan MA, Jick SS. Hepatitis B vaccination and multiple sclerosis: the jury is still out. Pharmacoepidemiol Drug Saf. 2006;15:653-5.